Lantheus Holdings, Inc. has recently released its 10-K report for the fiscal year ended December 31, 2024. The company, founded in 1956 and based in Bedford, Massachusetts, focuses on developing, manufacturing, and commercializing diagnostic and therapeutic products that aid in the diagnosis and treatment of heart, cancer, and other diseases worldwide. Its product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
In the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" section of the 10-K report, Lantheus highlighted several significant developments in 2025. These included the sale of its single-photon emission computerized tomography ("SPECT") business to SHINE Technologies, LLC for up to $155.0 million, the appointment of Mary Anne Heino as the new Chief Executive Officer following the retirement of former CEO Brian Markison, and various strategic transactions and agreements. Notably, the company announced a Prescription Drug User Fee Act ("PDUFA") target action date of March 29, 2026, for LNTH-2501, a diagnostic kit for the preparation of Gallium-68 ("Ga-68") edotreotide injection, and the acceptance of a New Drug Application ("NDA") for MK-6240, its registrational F-18 tau-targeted PET imaging agent for the detection of tau neurofibrillary tangle pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease.
Furthermore, Lantheus disclosed its share repurchase program, with the Board authorizing a program to repurchase up to $400.0 million of shares of its common stock through December 31, 2027. The company also completed the acquisition of Life Molecular Imaging Limited, including Neuraceq, an Alzheimer’s disease radiodiagnostic, for an upfront payment of $355.2 million in cash, with potential additional earn-out and milestone payments of up to $400.0 million. Additionally, Lantheus acquired Evergreen Theragnostics, Inc. for an upfront payment of $276.4 million in cash, with potential additional payments of up to $727.5 million based on specified milestones. The company also acquired NAV-4694, an investigational late-stage F-18-labeled PET imaging agent targeting beta amyloids in Alzheimer’s disease, and entered into an agreement with Radiopharm Theranostics Limited to acquire all of Radiopharm’s rights to two licensed preclinical assets for an upfront payment of $2.0 million.
These developments illustrate Lantheus' strategic focus on expanding its product portfolio, advancing its pipeline of radiopharmaceuticals, and strengthening its position within the radiopharmaceutical industry. The market has reacted to these announcements by moving the company's shares -1.79% to a price of $64.25. Check out the company's full 10-K submission here.
